A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis

N A Kennedy; E Rhatigan; I D R Arnott; C L Noble; A G Shand; J Satsangi; C W Lees

doi:10.1111/apt.12511

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis

N A Kennedy, E Rhatigan, I D R Arnott, C L Noble, A G Shand, J Satsangi, C W Lees

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Thiopurines maintain remission and modify disease course in inflammatory bowel disease. Use is limited by intolerance and subsequent drug withdrawal in approximately 17% of patients treated with azathioprine. Previous case series have addressed the success rates of re-treatment with mercaptopurine in these individuals.

Original language	English
Pages (from-to)	1255-66
Number of pages	12
Journal	Alimentary Pharmacology and Therapeutics
Volume	38
Issue number	10
DOIs	https://doi.org/10.1111/apt.12511
Publication status	Published - Nov 2013

Access to Document

10.1111/apt.12511

Cite this

Kennedy, N. A., Rhatigan, E., Arnott, I. D. R., Noble, C. L., Shand, A. G., Satsangi, J., & Lees, C. W. (2013). A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Alimentary Pharmacology and Therapeutics, 38(10), 1255-66. https://doi.org/10.1111/apt.12511

@article{20c8fcfc9c054f589b5f16e52e744ce9,

title = "A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis",

abstract = "Thiopurines maintain remission and modify disease course in inflammatory bowel disease. Use is limited by intolerance and subsequent drug withdrawal in approximately 17% of patients treated with azathioprine. Previous case series have addressed the success rates of re-treatment with mercaptopurine in these individuals.",

author = "Kennedy, {N A} and E Rhatigan and Arnott, {I D R} and Noble, {C L} and Shand, {A G} and J Satsangi and Lees, {C W}",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = nov,

doi = "10.1111/apt.12511",

language = "English",

volume = "38",

pages = "1255--66",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "10",

}

Kennedy, NA, Rhatigan, E, Arnott, IDR, Noble, CL, Shand, AG, Satsangi, J & Lees, CW 2013, 'A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis', Alimentary Pharmacology and Therapeutics, vol. 38, no. 10, pp. 1255-66. https://doi.org/10.1111/apt.12511

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. / Kennedy, N A; Rhatigan, E; Arnott, I D R et al.
In: Alimentary Pharmacology and Therapeutics, Vol. 38, No. 10, 11.2013, p. 1255-66.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine

T2 - an observational study, systematic review and meta-analysis

AU - Kennedy, N A

AU - Rhatigan, E

AU - Arnott, I D R

AU - Noble, C L

AU - Shand, A G

AU - Satsangi, J

AU - Lees, C W

PY - 2013/11

Y1 - 2013/11

N2 - Thiopurines maintain remission and modify disease course in inflammatory bowel disease. Use is limited by intolerance and subsequent drug withdrawal in approximately 17% of patients treated with azathioprine. Previous case series have addressed the success rates of re-treatment with mercaptopurine in these individuals.

AB - Thiopurines maintain remission and modify disease course in inflammatory bowel disease. Use is limited by intolerance and subsequent drug withdrawal in approximately 17% of patients treated with azathioprine. Previous case series have addressed the success rates of re-treatment with mercaptopurine in these individuals.

U2 - 10.1111/apt.12511

DO - 10.1111/apt.12511

M3 - Article

C2 - 24117596

SN - 0269-2813

VL - 38

SP - 1255

EP - 1266

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 10

ER -

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis

Abstract / Description of output

Access to Document

Fingerprint

Cite this